Leading Indian contract manufacturer of active pharmaceutical ingredients (APIs) for global generic and innovator drugmakers.
Leading Indian contract manufacturer of active pharmaceutical ingredients (APIs) for global generic and innovator drugmakers.
Sells active ingredients, the chemical that makes a drug work, to generic makers, and manufactures custom molecules for innovator drugmakers under long-term confidential supply arrangements. Most of its sales are exports. The founder, Murali Divi, and his family remain the controlling shareholders.
In one line: India's Lonza / Catalent for API/CDMO manufacturing.
Moat: narrow (process know-how, regulatory licence, scale). US FDA/EU-approved manufacturing scale and complex-chemistry expertise create high qualification barriers.
Headquarters: Hyderabad, India · Founded: 1990 · Employees: 19,292
Size Divi's Laboratories (DIVISLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $31.3B, the 30th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹11,049 on 18 Nov 2026.
Performance Over six months the shares gained 59.9%, against +8.2% for the median peer and +3.8% for the India market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 21.6% over the last twelve months (peer median +16.4%); the operating margin is 33.9% (peer median 17.8%).
Valuation It trades at 73.5× forward earnings against a peer median of 19.8× (most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +38 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.7 points above its cost of capital (12.9% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹122B | ₹105B | ₹93.6B | ₹78.3B | ₹77.5B |
| Revenue growth | — | +13% | +19% | +1% | — |
| Gross profit | ₹58.5B | ₹36.5B | ₹31.9B | ₹24.1B | ₹25.5B |
| EBITDA | ₹46.5B | ₹34.8B | ₹30.4B | ₹23.3B | ₹24.1B |
| Net income | ₹33.6B | ₹25.7B | ₹21.9B | ₹16.0B | ₹18.2B |
| Free cash flow | n/a | ₹4.97B | ₹5.08B | ₹5.56B | ₹21.9B |
| Capital expenditure | n/a | ₹25.2B | ₹14.4B | ₹10.0B | ₹4.73B |
| Total debt | ₹60.0M | ₹70.0M | ₹40.0M | ₹30.0M | ₹32.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| Laurus Labs LAURUSLABS.NS | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% |
| Syngene International SYNGENE.NS | $1.88B | -8% | -6% | 13% | 70.7× | 36.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DIVISLAB.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.6% | +3.9% | 2nd highest of 21 |
| 6-month return | +59.9% | +8.2% | highest of 21 |
| Distance from 52-week high | -6.5% | -10.3% | 8th highest of 21 |
| Revenue growth (TTM) | +21.6% | +16.4% | 9th highest of 21 |
| Operating margin | 33.9% | 17.8% | 4th highest of 21 |
| Forward P/E | 73.5× | 19.8× | most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 47.1% | 9.6% | most demanding of 19 |
| Growth delivered (Del g) | +8.9% | +11.1% | 9th lowest of 19 |
| Hurdle (Req g minus delivered) | +38.2 pp | +1.5 pp | most demanding of 19 |
| ROIC minus cost of capital | +6.7 pp | +4.8 pp | 9th highest of 21 |
| EV / EBITDA | 62.5× | 21.0× | most expensive of 18 |
| Net debt / EBITDA | -0.5× | 0.2× | 7th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% | +8.9% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% | +17.1% |
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% | +11.4% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% | +2.2% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% | +14.0% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% | +3.7% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 38.4× | 28.9% | +26.1% |
| Jiangsu Hengrui Pharmaceuticals 1276.HK | Hong Kong | $44.9B | -24% | +11% | 27% | 28.1× | 9.1% | +2.0% |
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Alnylam Pharmaceuticals ALNY | United States | $20.0B | -50% | +56% | 20% | 21.2× | 0.5% | +49.8% |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Innovent Biologics 1801.HK | Hong Kong | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% | +26.8% |